June 28, 2021
Chugai Pharmaceutical said on June 25 that its immunosuppressant CellCept (mycophenolate mofetil) has earned an additional indication for graft versus host disease (GVDH) in hematopoietic stem-cell transplantation (HSCT) both in adults and children. The new indication was developed at the...read more